

Supplementary information


Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Linda Söderberg¹, Malin Johannesson¹, Eleni Gkanatsiou¹, Patrik Nygren¹, Nicolas Fritz¹,
Olof Zachrisson¹, Adeline Rachalski¹, Anne-Sophie Svensson¹, Emily Button¹, Giacomo
Dentoni¹, Gunilla Osswald¹, Lars Lannfelt^{1,2}, Christer Möller¹

¹BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.


²Dept. of Public Health/Geriatrics, Uppsala University, 751 85, Uppsala, Sweden.

Supplementary Fig. 1



Supplementary Figure 1. IP-MALDI analyses of the FA-extracted pellet fractions from leptomeningeal tissues of AD subjects. **a**, Mass spectra for the indicated study subjects showing Aβ-assigned peaks. **b**, The relative abundance of the Aβ peptides identified in each pellet fraction sample (average of all subjects in **a**), as compared with the water-soluble extract from the same individual (data presented in Fig. 4).

Supplementary Fig. 2



Supplementary Figure 2. Schematic outline of the steps used to isolate and characterize CAA A β fibrils from human leptomeningeal tissue. Repeated water extraction of the tissue generated ten water fractions. The A β content of each fraction was analyzed using the V-PLEX® A β peptide panel 1 (4G8) assay (MSD). Fractions with high A β levels (usually fractions 2 to 6) were pooled, generating a representative sample from each subject for use in subsequent analyses. In a supplementary characterization, the final pellet that remained after all the water extractions had been completed was extracted in 70% formic acid prior to peptide characterization using immunoprecipitation (IP) matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI). IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; CLSM, confocal laser scanning microscopy; SPR, surface plasmon resonance.

Supplementary Table 1: SPR kinetics of antibody binding to CAA A β fibrils

AD009			
Antibody	k_{on} (M⁻¹s⁻¹)	k_{off} (s⁻¹)	K_{D1} (nM)
Aducanumab	$3.36 \pm 1.20 \times 10^5$	$1.14 \pm 0.28 \times 10^{-1}$	358 ± 71.7
Bapineuzumab	$6.72 \pm 7.86 \times 10^5$	$1.31 \pm 0.83 \times 10^{-3}$	5.96 ± 4.96
Crenezumab	ND	ND	ND
Donanemab	$1.25 \pm 0.37 \times 10^4$	$3.08 \pm 0.39 \times 10^{-2}$	728 ± 119
Gantenerumab	$6.46 \pm 1.41 \times 10^4$	$3.01 \pm 0.71 \times 10^{-2}$	471 ± 57.0
Lecanemab	$5.36 \pm 2.73 \times 10^4$	$3.91 \pm 1.30 \times 10^{-2}$	764 ± 134
Solanezumab	ND	ND	ND

AD062			
Antibody	k_{on} (M⁻¹s⁻¹)	k_{off} (s⁻¹)	K_{D1} (nM)
Aducanumab	$8.53 \pm 3.47 \times 10^4$	$1.03 \pm 0.41 \times 10^{-1}$	1220 ± 282
Bapineuzumab	ND	ND	ND
Crenezumab	ND	ND	ND
Donanemab	ND	ND	ND
Gantenerumab	$3.29 \pm 0.40 \times 10^4$	$4.59 \pm 0.48 \times 10^{-2}$	1400 ± 92.6
Lecanemab	ND	ND	ND
Solanezumab	ND	ND	ND

AD090			
Antibody	k_{on} (M⁻¹s⁻¹)	k_{off} (s⁻¹)	K_{D1} (nM)
Aducanumab	$1.33 \pm 1.00 \times 10^6$	$5.48 \pm 3.01 \times 10^{-2}$	54.9 ± 31.3
Bapineuzumab	$9.93 \pm 10.1 \times 10^5$	$9.10 \pm 4.73 \times 10^{-5}$	0.17 ± 0.13
Crenezumab	ND	ND	ND
Donanemab	$2.28 \pm 1.23 \times 10^4$	$8.29 \pm 2.84 \times 10^{-3}$	465 ± 367
Gantenerumab	$7.71 \pm 4.23 \times 10^4$	$2.29 \pm 0.89 \times 10^{-2}$	347 ± 132
Lecanemab	$7.96 \pm 1.44 \times 10^4$	$8.35 \pm 1.14 \times 10^{-2}$	1060 ± 160
Solanezumab	ND	ND	ND

AD021			
Antibody	k_{on} (M⁻¹s⁻¹)	k_{off} (s⁻¹)	K_{D1} (nM)
Aducanumab	$2.52 \pm 0.18 \times 10^5$	$1.38 \pm 0.08 \times 10^{-1}$	548 ± 36.7
Bapineuzumab	$3.33 \pm 0.21 \times 10^5$	$9.83 \pm 4.70 \times 10^{-5}$	0.30 ± 0.16
Crenezumab	$8.30 \pm 2.62 \times 10^3$	$1.53 \pm 1.02 \times 10^{-2}$	2020 ± 1540
Donanemab	$2.53 \pm 1.43 \times 10^4$	$3.02 \pm 1.18 \times 10^{-2}$	1260 ± 192
Gantenerumab	$7.49 \pm 0.58 \times 10^4$	$2.92 \pm 0.34 \times 10^{-2}$	390 ± 22.0
Lecanemab	$1.28 \pm 0.11 \times 10^5$	$2.18 \pm 0.12 \times 10^{-2}$	170 ± 9.85
Solanezumab	ND	ND	ND

Data shown as mean \pm SD. ND: not detected.

k_{on} : association rate constant; k_{off} : dissociation rate constant; K_{D1} : dissociation constant.